Seoul Viosys KRX:092190KOSDAQ
서울바이오시스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Seoul Viosys reported revenue of ₩214bn, up 13.8% year on year, and operating profit of ₩10.2bn. Seoul Viosys (서울바이오시스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Seoul Viosys quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩214bn | +13.8% | ₩10.2bn | ₩8.2bn |
| Q1 2026 | ₩188bn | +11.9% | ₩10.4bn | ₩10.3bn |
| Q4 2025 derived | ₩220bn | +23.2% | ₩15.1bn | ₩11.5bn |
| Q3 2025 | ₩188bn | +1.7% | −₩779m | −₩4.1bn |
| Q2 2025 | ₩188bn | -0.1% | −₩917m | −₩3.7bn |
| Q1 2025 | ₩168bn | +13.6% | −₩13.1bn | −₩17.3bn |
| Q4 2024 derived | ₩179bn | +23.2% | −₩4.0bn | −₩17.6bn |
| Q3 2024 | ₩184bn | +44.8% | ₩5.2bn | ₩9.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Seoul Viosys top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Seoul Viosys news Korean headlines
No articles yet.